NGL Fine-Chem Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company achieved a standalone revenue of ₹127.51 crores and a consolidated net profit of ₹13.5 crores. This performance indicates a robust recovery and significant operational efficiency compared to previous periods. The following table provides a comparative analysis of the financial results for the current quarter relative to the previous quarter and the corresponding quarter of the previous year.

*Note: Percentage changes are based on reported trends in operational data provided in the financial filing and related market updates.

NGL Fine-Chem Limited, established in 1981 and headquartered in Mumbai, is a prominent manufacturer of Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage forms, with a primary focus on the animal health sector. The company operates five advanced manufacturing facilities in Maharashtra and holds a significant presence in global markets, exporting to over 60 countries. NGL is recognized for its deep backward integration and commitment to quality, maintaining various international certifications including WHO-GMP and ISO standards. The company continues to invest in R&D and capacity expansion to support its growth in both veterinary and human health segments.